Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eosinophilic Esophagitis | 4 | 2022 | 8 | 2.280 |
Why?
|
| Esophagus | 5 | 2018 | 47 | 1.300 |
Why?
|
| Crohn Disease | 3 | 2020 | 106 | 1.110 |
Why?
|
| Proton Pump Inhibitors | 2 | 2022 | 47 | 0.990 |
Why?
|
| Gastrointestinal Diseases | 1 | 2024 | 69 | 0.800 |
Why?
|
| Autism Spectrum Disorder | 1 | 2024 | 181 | 0.660 |
Why?
|
| Epithelial Cells | 4 | 2018 | 413 | 0.620 |
Why?
|
| Fluticasone | 2 | 2018 | 17 | 0.610 |
Why?
|
| Lymphoma, Follicular | 1 | 2020 | 18 | 0.610 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 168 | 0.540 |
Why?
|
| Abdominal Abscess | 2 | 2017 | 12 | 0.540 |
Why?
|
| Budesonide | 1 | 2018 | 22 | 0.530 |
Why?
|
| Duodenal Ulcer | 1 | 2016 | 3 | 0.500 |
Why?
|
| Neuroendocrine Tumors | 1 | 2016 | 20 | 0.490 |
Why?
|
| Peanut Hypersensitivity | 1 | 2016 | 6 | 0.480 |
Why?
|
| Desensitization, Immunologic | 1 | 2016 | 13 | 0.480 |
Why?
|
| Glycation End Products, Advanced | 1 | 2016 | 19 | 0.470 |
Why?
|
| Adolescent | 9 | 2024 | 6329 | 0.470 |
Why?
|
| Vomiting | 1 | 2016 | 139 | 0.440 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 410 | 0.440 |
Why?
|
| Fatty Liver | 1 | 2016 | 111 | 0.430 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2016 | 91 | 0.430 |
Why?
|
| Child | 9 | 2024 | 4620 | 0.400 |
Why?
|
| Child, Preschool | 5 | 2024 | 2064 | 0.390 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 354 | 0.380 |
Why?
|
| Inflammation | 2 | 2018 | 1193 | 0.370 |
Why?
|
| Tissue Engineering | 3 | 2018 | 148 | 0.340 |
Why?
|
| Esophagitis | 1 | 2009 | 9 | 0.310 |
Why?
|
| Eosinophils | 1 | 2009 | 49 | 0.300 |
Why?
|
| Eosinophilia | 1 | 2009 | 37 | 0.300 |
Why?
|
| Endoscopy | 3 | 2018 | 92 | 0.270 |
Why?
|
| Obesity | 1 | 2016 | 1276 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2024 | 6926 | 0.250 |
Why?
|
| Male | 11 | 2024 | 31177 | 0.240 |
Why?
|
| Administration, Oral | 2 | 2018 | 371 | 0.230 |
Why?
|
| Humans | 15 | 2024 | 65452 | 0.230 |
Why?
|
| Constipation | 1 | 2024 | 15 | 0.210 |
Why?
|
| Abdominal Pain | 1 | 2024 | 99 | 0.200 |
Why?
|
| Endoscopy, Digestive System | 2 | 2016 | 33 | 0.200 |
Why?
|
| Biopsy | 2 | 2018 | 458 | 0.190 |
Why?
|
| Infliximab | 2 | 2020 | 50 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 990 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2024 | 445 | 0.160 |
Why?
|
| Gastroenterology | 1 | 2020 | 29 | 0.160 |
Why?
|
| Methotrexate | 1 | 2020 | 80 | 0.150 |
Why?
|
| Esophageal Atresia | 1 | 2018 | 9 | 0.140 |
Why?
|
| Polyurethanes | 1 | 2018 | 29 | 0.140 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 128 | 0.140 |
Why?
|
| 3T3 Cells | 1 | 2018 | 111 | 0.140 |
Why?
|
| Tissue Scaffolds | 2 | 2018 | 91 | 0.140 |
Why?
|
| Esophagoscopy | 1 | 2018 | 26 | 0.130 |
Why?
|
| Integrins | 1 | 2018 | 109 | 0.130 |
Why?
|
| Female | 7 | 2024 | 34188 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2018 | 5806 | 0.130 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 159 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 179 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 296 | 0.130 |
Why?
|
| Esophageal Diseases | 1 | 2017 | 16 | 0.130 |
Why?
|
| Arachis | 1 | 2016 | 6 | 0.120 |
Why?
|
| Diet Therapy | 1 | 2016 | 15 | 0.120 |
Why?
|
| Drainage | 1 | 2017 | 153 | 0.120 |
Why?
|
| Biomarkers | 1 | 2022 | 1483 | 0.120 |
Why?
|
| Peroxidase | 1 | 2016 | 70 | 0.110 |
Why?
|
| Leptin | 1 | 2016 | 88 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 106 | 0.110 |
Why?
|
| Stem Cells | 1 | 2017 | 276 | 0.110 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 328 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 202 | 0.110 |
Why?
|
| Weight Gain | 1 | 2016 | 166 | 0.110 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 180 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 795 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2016 | 324 | 0.110 |
Why?
|
| Weight Loss | 1 | 2016 | 276 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 308 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1008 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2016 | 299 | 0.100 |
Why?
|
| Mice | 2 | 2018 | 11137 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 604 | 0.100 |
Why?
|
| Urachal Cyst | 1 | 2012 | 2 | 0.100 |
Why?
|
| Intestinal Fistula | 1 | 2012 | 13 | 0.090 |
Why?
|
| Infant | 1 | 2018 | 1701 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2020 | 802 | 0.090 |
Why?
|
| Animals | 4 | 2018 | 21379 | 0.090 |
Why?
|
| Colitis, Ulcerative | 1 | 2012 | 76 | 0.090 |
Why?
|
| Colectomy | 1 | 2012 | 123 | 0.080 |
Why?
|
| Liver | 1 | 2016 | 871 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 110 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 806 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 381 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 33 | 0.080 |
Why?
|
| Androstadienes | 1 | 2009 | 43 | 0.080 |
Why?
|
| Clostridium Infections | 1 | 2010 | 49 | 0.070 |
Why?
|
| Community-Acquired Infections | 1 | 2010 | 95 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 1658 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 4834 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1334 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2188 | 0.040 |
Why?
|
| Competency-Based Education | 1 | 2020 | 31 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 102 | 0.040 |
Why?
|
| Swine | 1 | 2018 | 396 | 0.030 |
Why?
|
| Incidence | 2 | 2012 | 1429 | 0.030 |
Why?
|
| Cell Count | 1 | 2017 | 128 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 731 | 0.030 |
Why?
|
| Polyglycolic Acid | 1 | 2015 | 18 | 0.030 |
Why?
|
| Bioreactors | 1 | 2015 | 36 | 0.030 |
Why?
|
| Biomimetics | 1 | 2015 | 31 | 0.030 |
Why?
|
| Polyesters | 1 | 2015 | 45 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2015 | 75 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2015 | 62 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2012 | 2111 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 624 | 0.020 |
Why?
|
| Ileocecal Valve | 1 | 2012 | 1 | 0.020 |
Why?
|
| Ileal Diseases | 1 | 2012 | 6 | 0.020 |
Why?
|
| Calcineurin Inhibitors | 1 | 2012 | 22 | 0.020 |
Why?
|
| Purines | 1 | 2012 | 43 | 0.020 |
Why?
|
| Wound Infection | 1 | 2012 | 29 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2012 | 45 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 2012 | 52 | 0.020 |
Why?
|
| Colitis | 1 | 2012 | 77 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 1996 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2305 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 182 | 0.020 |
Why?
|
| Metronidazole | 1 | 2010 | 10 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 994 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 133 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2010 | 97 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 743 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 302 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1591 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1451 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 875 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1564 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2492 | 0.020 |
Why?
|
| Mass Screening | 1 | 2010 | 700 | 0.010 |
Why?
|
| United States | 1 | 2010 | 8148 | 0.010 |
Why?
|